drugset / Trial / NCT00401947
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection
Phase 2
Terminated
30 enrolled
Alexion Pharmaceuticals, Inc.
Achillion, a wholly owned subsidiary of Alexion · collab
RandomizedSingle-groupDouble-blindTreatment
Summary
The purpose of this study was to investigate the safety, tolerability, pharmacokinetics (PK), and antiviral activity of multiple doses of ACH-0137171 in participants with chronic hepatitis C virus (HCV) infection.
Timeline
- Start
- 2006-11-30
- Primary completion
- —
- Completion
- 2007-03-31
Outcome
Outcome not reported
Stopped: “Nephrotoxicity”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACH-0137171 | Unknown | 300 mg | — |
| Subject | ACH-0137171 | Unknown | 600 mg | — |